You have read all your free articles, to continue reading subscribe to read the rest of this content.
The trial, the second of two pivotal Phase III trials for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), did not meet the primary endpoint of a statistically-significant reduction of exacerbations. This news follows the announcementAlready a subscriber Login You have read all your free articles,…
The medical cooling devices company announce that it has completed patient recruitment in the multi-center pivotal trial of the patented DigniCap System. Dignitana is conducting a Premarket Approval (PMA), a regulatory process with the aim to obtain product and market approval for the DigniCap SyAlready a subscriber Login You have…
Phase II efficacy and safety data in patients with Mycosis Fungoides (MF) type early-stage Cutaneous T-cell Lymphoma (CTCL) demonstrated that remetinostat gel 1%, when applied topically twice daily, reduced the severity of CTCL skin lesions. Remetinostat also caused a clinically significant reducAlready a subscriber Login You have read all your…
A new clinical trial shows that a two-stent technique for treatment of bifurcation lesions with a large stenotic side branch was not associated with significant improved outcomes compared to a provisional stenting approach. The findings from the Nordic-Baltic Bifurcation IV study were presented aAlready a subscriber Login You have read…
